Cyclic Phosphatidic Acids Suppressing Demyelination
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for demyelinating diseases, such as multiple sclerosis, lack effective agents to suppress demyelination of nerve axons, leading to significant neurological symptoms and complications.
Innovation Solution
Cyclic phosphatidic acids, carba-cyclic phosphatidic acids, and thia-cyclic phosphatidic acids, or their salts, are used as therapeutic agents to suppress demyelination of nerve axons, offering a novel approach for treating demyelinating diseases by administering these compounds to patients.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional treatments for demyelinating diseases are used, then existing therapeutic options are maintained, but effective suppression of demyelination is not achieved
Solution Approach 1:
The patent applies parameter changes by modifying the chemical structure of phosphatidic acid to create cyclic phosphatidic acid derivatives with specific cyclic ester bonds between phosphoric acid and hydroxyl groups. This structural parameter change results in compounds with enhanced ability to suppress demyelination compared to conventional treatments, directly addressing the effectiveness gap in existing therapies
2Object-affected harmful factors
If no specific anti-demyelination agents are available, then treatment options remain limited, but neurological symptoms and complications worsen
Solution Approach 1:
The patent introduces cyclic phosphatidic acid derivatives as intermediary substances that mediate between the immune system and nerve axons. These compounds act as selective inhibitors of demyelination by interfering with the pathological process while preserving normal nerve function, thereby providing a new therapeutic mechanism where none effectively existed before
Data Source
AI summary
It is an object of the present invention to provide a novel therapeutic agent for demyelinating disease which has an action to suppress demyelination of nerve axons. According to the present invention, a therapeutic agent for demyelinating disease which comprises cyclic phosphatidic acids, carba-cyclic phosphatidic acids, thia-cyclic phosphatidic acids, or a salt thereof is provided.